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Anaplastic lymphoma kinase-(ALK-) positive large B-cell lymphoma (ALK+ LBCL) is a rare, aggressive tumor characterized
by an immunoblastic or plasmablastic morphologic appearance, expression of ALK, CD138, CD45, EMA, and often IgA
by immunohistochemistry, and characteristic chromosomal translocations or rearrangements involving the ALK locus. The
morphologic and immunophenotypic overlap of this tumor with other hematologic and nonhematologic malignancies may result
in misdiagnosis. The tumor has been identiﬁed in both pediatric and adult populations and demonstrates a male predominance.
Presentation is most often nodal, particularly cervical. No association with immunocompromise or geographic location has been
recognized. The most common gene rearrangement is between clathrin and ALK (t(2;17)(p23;q23)), resulting in the CLTC-
ALK chimeric protein, although other fusions have been described. Response to conventional chemotherapy is poor. The recent
introduction of the small molecule ALK inhibitor, crizotinib, may provide a potential new therapeutic option for patients with this
disease.
1.Introduction
Anaplastic lymphoma kinase-(ALK-) positive large B-cell
lymphoma (ALK+ LBCL) was ﬁrst described by Delsol and
colleagues in 1997 [1] and is now listed as a distinct entity in
the 2008 WHO Classiﬁcation of Tumours of Haematopoietic
and Lymphoid Tissues [2]. ALK+ LBCL is an aggressive
tumor with a poor response to conventional therapies. Al-
t h o u g hi ta p p e a r st ob ev e r yr a r e ,i tm a yi nf a c tb eu n d e r -
recognized due to its morphologic and immunophenotypic
overlap with other hematologic and nonhematologic entities
Awareness of this diagnosis, particularly in a new era of ALK
inhibitor therapies, is necessary for hematopathologists as
well as general surgical pathologists.
2.ClinicalFeaturesandEpidemiology
Fewer than 100 cases of ALK+ LBCL have been described in
the literature (reviewed in [3–6], subsequent cases reported
in [7–13]). The neoplasm has been diagnosed in both
pediatric and adult age groups, ranging in age from 9 to 85
years old, with a median age of 37 to 44.5 years, and with
a male predominance of 3–5:1. The proportion of patients
under age 18 has been found to comprise approximately
15–20% of the total. One conﬁrmed case occurring in a
patient with the human immunodeﬁciency virus (HIV) has
been reported [12]. In general, patients do not appear to
be immunocompromised. Furthermore, patients with this
tumor do not appear to be restricted geographically; cases
have been reported from Europe, the United States, and Asia.
Our institution recently diagnosed ALK+ LBCL on a biopsy
sample from a 29-year-old man living in Rwanda [S. Rodig,
personal communication].
ALK+ LBCL most commonly presents in lymph nodes,
particularly cervical, although extranodal involvement has
been reported in a wide variety of sites, including the GI
tract, epidural space, ovaries, skeleton, nasopharyngeal or
nasal area, tongue, brain, and liver. Bone marrow and splen-
ic involvement have also been described. The majority of pa-
tients present with advanced stage disease. No tumors have
been positive for the Epstein-Barr virus (EBV) by in situ hy-
bridization or for human herpes virus-8 (HHV8) by immu-
nohistochemistry [5, 6].2 Advances in Hematology
3.Diagnosis
The diagnosis of ALK+ LBCL requires synthesis of the mor-
phologic features and immunohistochemical ﬁndings and
is aided by cytogenetic data when available. The neoplastic
cells are intermediate to large sized, and immunoblastic- or
plasmablastic-appearing with round nuclei, dispersed chro-
matin, a single, prominent, central nucleolus and moderate
amounts of eosinophilic to amphophilic cytoplasm (Figure
1) .T h et u m o rg r o w si ns h e e t si nn o d a la n de x t r a n o d a ls i t e s ,
and, within the lymph node, often demonstrates sinusoidal
invasion. The tumor cells are almost always negative for
CD20 and CD79a but are always positive for CD138 and
CD38, consistent with a postgerminal center phenotype
(Figure 2). ALK stains 100% of tumors, and its staining pat-
tern may be suggestive of the underlying cytogenetic abnor-
mality (see Genetics and Pathogenesis). CD45, EMA, and
MUM-1 are also frequently positive, and CD4 staining may
be seen. The tumors often express IgA with monotypic light
chain restriction. Other markers, including keratins, have
infrequently been reported.
Duetothemorphologicandimmunophenotypicoverlap
with other hematologic and nonhematologic malignancies,
this neoplasm may be misdiagnosed. Indeed, several cases
in the literature were initially classiﬁed as poorly diﬀeren-
tiated or anaplastic carcinoma [6], ALK-positive anaplastic
large cell lymphoma (ALK+ ALCL) [14], or extramedullary
plasmacytoma [5, 10]. Further, the plasmablastic morpho-
logic features overlap with other aggressive large B-cell
lymphomas with plasmablastic diﬀerentiation. It is possible
that the small number of cases in the literature may
represent underreporting due to failure of recognition of the
entity. Immunohistochemical studies can greatly assist in the
interpretation of these tumors (Table 1).
4.GeneticsandPathogenesis
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase of
the insulin receptor superfamily. In all cases of ALK+ LBCL
in which cytogenetic or molecular attempts were successful,
chromosomal translocation or rearrangement involving the
ALK locus has been identiﬁed by karyotype, FISH, and/or
RT-PCR.Althoughitwasinitiallysuggestedthatafull-length
ALK protein was expressed by these tumors, it is now clear
that these tumors commonly express the product of a fusion
gene that incorporates the 3  portion of ALK encoding the
tyrosine kinase domain.
Several genetic partners fused to ALK have been des-
cribed. The most common is clathrin (CLTC-ALK), the pro-
duct of t(2;17)(p23;q23) (ﬁrst described in [15–17]). Inter-
estingly, this translocation has been described in less than
1% of cases of ALK+ ALCL [2] and has also been identiﬁed
in inﬂammatory myoﬁbroblastic tumors (IMT) [18]. In
both ALK+ LBCL and ALK+ ALCL, immunohistochemical
staining with anti-ALK antibodies gives a granular cyto-
plasmic pattern in neoplastic cells because clathrin encodes
for a coated vesicle protein involved in intracellular trans-
port. Less commonly described in ALK+ LBCL is the nucleo-
phosmin-ALK (NPM-ALK) fusion protein, resulting from
t(2;5)(p23;q35) [9, 19, 20]. In contrast, NPM-ALK is the
most common chimeric protein in ALK+ ALCL [2]. In both
ALK+ LBCL and ALK+ ALCL bearing this chimeric protein,
immunohistochemical staining with ALK gives a nuclear
and cytoplasmic staining pattern. As in ALK+ ALCL, the
distinct ALK staining patterns may act as a surrogate for the
underlying gene rearrangement in ALK+ LBCL.
As awareness of this rare lymphoma increases, investi-
gators are using more sensitive and directed techniques to
conﬁrm the presence of ALK rearrangements in tumors that
immunophenotypically are compatible with the diagnosis.
Van Roosbroeck and colleagues utilized sophisticated tech-
nique including metaphase FISH, RT-PCR, and 5  RACE
PCR to identify a cryptic SEC31A-ALK fusion generated by
insertion of the 5  end of SEC31A (4q21) upstream of the
3  end of ALK [9]. This had previously only been describ-
ed in one case of IMT [21] and was subsequently conﬁrmed
in a second case of ALK+ LBCL by Bedwell and colleagues
[8]. In all three cases, the SEC31A-ALK fusion was the result
of complex rearrangements rather than a single reciprocal
translocation event (which would not be possible due to the
opposite transcriptional orientation of ALK and SEC31A);
this likely accounts for the rarity of both its occurrence
and its detection. As pointed out by Van Roosbroeck et al.,
Stachurski and colleagues’ report of an ALK+ LBCL with
complex karyotype and cryptic insertion of 3 -ALK gene
sequences into chromosome 4q22-24 may, potentially, repre-
sent a SEC31A-ALK fusion [22]. In all cases, ALK immuno-
histochemical staining was granular cytoplasmic.
In addition to these reproducible genetic events, addi-
t i o n a lc a s er e p o r t sh a v ed e m o n s t r a t e d5  ALK gene deletion
[23]; duplication of the ALK gene region/additional copy
of chromosome 2 [24]; complex karyotype with two inde-
pendent ALK translocations: t(X;2)(q21;p23) and t(2;12)
(p23;q24.1) showing granular cytoplasmic ALK staining
[12]; SQSTM1-ALK, generated from t(2;5)(p23.1;q35.3),
showing diﬀuse cytoplasmic ALK staining with ill-demar-
cated spots [13].
Several experimental models support the role of ALK fu-
sion genes in disease pathogenesis. Expression of a SEC31A-
ALK constructintheinterleukin-3-(IL3-)dependentcellline
Ba/F3 permitted growth factor-independent growth upon
cessation of IL3 administration [9]. Addition of an ALK
inhibitor resulted in decreased ALK tyrosine phosphoryla-
tion and decreased phosphorylation of downstream eﬀectors
ERK1/2 and STAT3, and, less robustly, AKT and STAT5
[9]. STAT3, but not STAT5, has been found to be highly
hyperphosphorylated on tyrosine 705 in two cases of ALK+
LBCL with the CLTC-ALK fusion protein [7]. Injection
of 3T3 cells expressing SQSTM1-ALK into nude mice
produced subcutaneous tumors [13]. A CLTC-ALK-positive
DLBCL cell line, generated from a patient with systemic
relapsed disease, formed subcutaneous tumors in NOD-
SCID mice, which morphologically and immunophenotyp-
ically recapitulated the ALK+ LBCL phenotype, including
the granular cytoplasmic ALK staining pattern [14]. As in
ALK+ ALCL, one could hypothesize that ALK chimeric
proteins allow for constitutive activation of the ALK tyrosineAdvances in Hematology 3
(a) (b)
Figure 1: ALK+ LBCL morphology. (a) The tumor grows diﬀusely with a sheet-like architecture (400x, H&E). (b) The tumor cells are
intermediate to large sized with round nuclei, dispersed chromatin, centrally placed nucleoli and moderate amounts of amphophilic
cytoplasm (1000x, H&E).
(a) (b)
(c) (d)
(e) (f)
Figure 2:ALK+LBCLimmunohistochemicalproﬁle.AlltumorsarepositiveforALK(a)andCD138(b).CD20(c)isalmostalwaysnegative,
but MUM-1 (d) is frequently positive. IgA is often expressed (e). EMA can show focal to diﬀuse positivity (f). All microphotographs are
400x.4 Advances in Hematology
Table 1: Diﬀerential diagnosis of ALK+ LBCL and predominant staining patterns with several antibodies. This table summarizes the
predominant staining patterns for these entities, with the understanding that exceptional cases have been reported. Typically, ALK+ LBCL
demonstrates a postgerminal center phenotype and is negative for CD30. Rare cases expressing CD20, CD79a, or CD30 have been reported
[5].
ALK+ LBCL ALK+ ALCL DLBCL, NOS Poorly diﬀerentiated carcinoma Extramedullary
plasmacytoma
C D 4 5 +++ −
CD20 −−+ −
CD79a − ++
MUM-1 + +/−
CD138 + −− +/− +
ALK + + −− −
CD30 − ++ / −
EMA + + +/−
Keratin +/− +/−
EBER −−
kinaseindependentofligandbinding,resultinginunchecked
activation of downstream eﬀectors.
5.OutcomeandTreatmentStrategies
As opposed to ALK+ ALCL, which has an overall 5-year
survival rate approaching 80% [2], ALK+ LBCL has a
dismal prognosis and poor response to conventional therapy
regimens. Laurent and colleagues retrospectively analyzed
clinical outcome data in 31 patients diagnosed with ALK+
LBCL [6]. All patients with documented therapy (n = 30)
received cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) or CHOP-derived chemotherapy; 11
additionally received radiation therapy, and 3 underwent
subsequent autologous stem cell transplantation. The 5-year
survival rate was 25% with a median survival of 12 months
in advanced stage disease. Overall survival was signiﬁcantly
shorter for patients with stage III or IV disease as deﬁned
by the Ann Arbor staging system compared to those who
presented with stage I or II disease.
Another review of 46 published cases and 4 new cases
of ALK+ LBCL analyzed outcomes in 41 cases with available
treatment data [5]. Twelve of 32 patients treated with chem-
otherapy received CHOP; of these, 6 patients relapsed and
4 patients died of progressive lymphoma. Of all treated pa-
tients, eighteen (44%) had relapsed/refractory disease, and 7
of 8 patients who underwent salvage hematopoietic stem cell
transplantation (4 autologous, 1 allogeneic, 3 unspeciﬁed)
died between 3 and 44 months after diagnosis. Notably, a
subsequently published case report described relapse and
death within 100 days of front-line autologous transplanta-
tion after treatment with CHOP and radiation therapy [10].
Overall, Beltran and colleagues documented that 56% of
reported patients died, most commonly (90% of cases) due
to progressive lymphoma, with an overall survival time of 24
months. Similarly to Laurent and colleagues, they found that
the strongest correlative factor to survival was clinical stage
at presentation, calculating an 18-month median survival in
patients with advanced disease versus not reached in early-
stage presentations [5].
While a systematic, prospective study of treatment
regimens would be diﬃcult in this rare disease, it is apparent
from the reported literature that ALK+ LBCL is an aggressive
disease with poor response to conventional therapies. More
recently, interest has turned to the potential use of a new
class of drugs, namely, ALK inhibitors. In addition to ALK+
LBCL, mutations or gene rearrangements leading to growth-
factor-independent ALK activation have been implicated in
the oncogenesis of several neoplasms including ALK+ ALCL
[25], 50% of IMTs [26, 27], a subset of sporadic and familial
neuroblastoma [28, 29], and 5% of nonsmall cell lung
cancer (NSCLC) [30, 31]. The use of a small molecular ALK
inhibitor is an attractive possibility in these diseases, and the
potential is garnering excitement in the oncology ﬁeld.
Recently, and in a remarkably short time since the ﬁrst
description of the ALK rearrangement in NSCLC, the Food
and Drug Administration approved the use of crizotinib
(Xalkori Capsules, Pﬁzer, Inc.), the small-molecule dual
inhibitor of the c-Met and ALK receptor tyrosine kinases, for
the treatment of patients with locally advanced or metastatic
NSCLC with an ALK rearrangement [30]. Crizotinib has also
been tried on a case-by-case basis in other tumors. Butrynski
and colleagues recently reported a sustained partial response
in a patient with an ALK-translocated IMT, while no re-
sponsewasobservedinapatientwithanALK-non-rearrang-
ed IMT [32]. Gambacorti-Passerini and colleagues adminis-
tered crizotinib to two patients with relapsed ALK+ ALCL;
clinical improvement was seen within one week for both
patients, and complete response was sustained at six months
and ﬁve months, respectively [33].
There is some experimental evidence to suggest that
ALK inhibitors may be eﬃcacious in the treatment of
ALK+ LBCL. Upon identifying a SEC31A-ALK fusion in a
patient with ALK+ LBCL, Van Roosbroeck and colleagues
demonstrated that the selective ALK inhibitor NVP-TAE684
(TAE-684) could inhibit the growth of a Ba/F3 cell line
expressing the SEC31A-ALK construct in a dose-dependentAdvances in Hematology 5
manner [9, 34]. Cerchietti and colleagues established a cell
lineexpressingCLTC-ALK,themostcommonfusionprotein
identiﬁed in ALK+ LBCL, and demonstrated that TAE-684
could inhibit cell growth in vitro and could regress murine
tumor xenografts in vivo [14]. To date, no reports of the
use of crizotinib in patients with ALK+ LBCL have appeared
in the literature. However, at least one Phase 1B clinical
trial, studying the safety and clinical activity of crizotinib in
tumors with genetic events involving the ALK gene locus, is
currently recruiting patients (NCT01121588), and reference
was made to a patient enrolling in an inhibitor trial in a
recent case report [12].
6. Conclusion
ALK+ LBCL is a rare, aggressive B-cell lymphoma with
characteristic morphologic, immunophenotypic and cytoge-
netic/molecular ﬁndings. Awareness of this entity is impor-
tant in both the hematopathology and general surgical
pathology ﬁelds. Although response to conventional therapy
has been poor, the possibility of a targeted therapy provides
an intriguing option for patients with this disease.
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